| Ditemukan 629 dokumen dengan kata kunci 9185 |
Simpan CSV  |
|
Racial Disparity in Consultation, Treatment, and the Impact on Survival in Metastatic Colorectal Cancer
|
| No. Panggil: JNCI Journal of the National Cancer Institute; Volume 105, No.23, 4 December 2013: p.1814-1820 |
|
|
Koleksi: Artikel Internasional - Oxford ::
Cari yang mirip ::
Tambahkan ke Favorit ::
|
|
|
Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer
|
|
|
|
Secular Trends in Colon and Rectal Cancer Relative Survival
|
| No. Panggil: JNCI Journal of the National Cancer Institute; Volume 105, No.23, 4 December 2013: p.1806-1813 |
|
|
Koleksi: Artikel Internasional - Oxford ::
Cari yang mirip ::
Tambahkan ke Favorit ::
|
|
|
A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial
|
|
|
|
Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer
|
|
|
|
Prospective Study of Family History and Colorectal Cancer Risk by Tumor LINE-1 Methylation Level
|
| No. Panggil: JNCI Journal of the National Cancer Institute; Volume 105, No.2, 16 January, 2013: p.130-140 |
|
|
Koleksi: Artikel Internasional - Oxford ::
Cari yang mirip ::
Tambahkan ke Favorit ::
|
|
|
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
|
|
|
|
The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial and Its Associated Research Resource
|
| No. Panggil: JNCI Journal of the National Cancer Institute; Volume 105, No.22, 20 November 2013: p.1684-1693 |
|
|
Koleksi: Artikel Internasional - Oxford ::
Cari yang mirip ::
Tambahkan ke Favorit ::
|
|
|
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study
|
|
|
|
Current status of screening for colorectal cancer
|
|
|
Hasil Pencarian
